Latest news with #asperigimycins
The Independent
9 hours ago
- Health
- The Independent
Fungus dubbed ‘mummy's curse' could make a powerful cancer drug, new study reveals
Researchers believe that a fungus thought to be found in ancient tombs may provide a valuable new tool in the fight against cancer. The fungus Aspergillus flavus, sometimes dubbed the 'mummy's curse' for its potential link to the deaths of archaeologists who excavated famous tombs like that of King Tutankhamen in Egypt, shows promise in stopping cancers such as leukemia, according to a new study published Monday in Nature Chemical Biology from a team of scientists led by the University of Pennsylvania. 'Fungi gave us penicillin,' Sherry Gao, associate professor in chemical and biomolecular engineering and bioengineering at Penn, a senior author on the study, said in a statement. 'These results show that many more medicines derived from natural products remain to be found.' Over the course of their research, the scientists isolated and purified a new class of molecules derived from the fungus, asperigimycins, and tested them against common cancers in breast, liver, and lung cells. Even with no modification, two of the four asperigimycins in the experiment had 'potent' effects against leukemia cells, according to the university. Another variation, to which scientists added a fatty lipid molecule, performed as well as the longstanding Food and Drug Administration-approved leukemia drugs cytarabine and daunorubicin, the university added. Researchers believe these molecules, created inside the fungus's cellular machinery then modified by the study's authors, block some of the mechanisms of cell division, halting the unchecked cell growth that causes cancer. 'Cancer cells divide uncontrollably,' Gao added in the statement. 'These compounds block the formation of microtubules, which are essential for cell division.' Aspergillus flavus, which is commonly found in soil, can lead to lung infections in humans, especially among those with compromised immune systems, and infects a variety of agricultural crops. As a result, it is one of the most frequently isolated mold species in agriculture and medicine, according to Popular Science. The Penn team, which also included researchers from Rice University, the University of Pittsburg, the University of Texas, Washington University of St. Louis, Baylor College of Medicine, and the University of Porto, said its research was unique because it focused on a class of peptides more commonly studied in bacteria, rather than fungus. The research, which scientists hope to continue in animal models and potential human trials down the road, was funded by the National Institutes of Health, the biomedical research hub from which the Trump administration hopes to cut $18 billion in funding.
Daily Mail
10 hours ago
- Health
- Daily Mail
Scientists transform deadly ancient fungus into potential cancer cure
A deadly fungus dating back to ancient tombs could help treat blood cancer, researchers have revealed. Aspergillus flavus is a fungus that grows on dead plant tissue in soil, spreading to cereal grains, legumes and tree nuts. It's also been nicknamed the 'pharaohs' curse' after researchers studying the tombs of ancient kings over the past several decades have suddenly been struck by deadly respiratory issues. Killing up to 50 percent of those it strikes, the fungus is thought to 'eat people from the inside out,' and experts fear climate change may lead it to spread. But researchers in Pennsylvania and Texas have found polar opposite effects. In a newly released study, they found Aspergillus flavus produces interlocking ringed molecules they named asperigimycins. When tested against human leukemia cells, two of the four asperigimycins showed potent cancer-killing effects But when the researchers enhanced the asperigimycins by adding a lipid to it - a fatty molecule - the asperigimycins treated leukemia cells just as well as cytarabine and daunorubicin, two FDA-approved drugs that have been used to treat the cancer for decades. They believe asperigimycins may attack structures responsible for cell division, which normally causes healthy cells to mutate into cancerous ones. The team compared the surprising benefit of the deadly fungus to crucial advancements in treating diseases, such as the invention of penicillin. Aspergillus flavus has been nicknamed the 'pharaohs' curse' after researchers studying the tombs of ancient kings over the past several decades have suddenly been struck by deadly respiratory issues Dr Sherry Gao, senior study author and associate professor in chemical and biomolecular engineering and in bioengineering at the University of Pennsylvania, said: 'Fungi gave us penicillin. 'These results show that many more medicines derived from natural products remain to be found.' The findings come as 60,000 Americans are struck by leukemia every year and about 23,000 die. Aspergillus flavus was first thrust in the spotlight in the 1920s after a team of archeologists opened the tomb of King Tutankhamun in Egypt and suddenly become ill. After their deaths, rumors circulated of a curse. About 50 years later, in the 1970s, a dozen scientists opened the tomb of Casimir IV, who ruled Poland in latter half of the 15th century. A few weeks later, 10 of the researchers died. Later investigations revealed the presence of Aspergillus flavus. It's unclear how many people worldwide are affected by Aspergillus flavus, but it's believed to kill up to 50 percent of patients it infects by producing spores that attack the liver and lungs, especially in people who are immunocompromised. In the new study, published Monday in the journal Nature Chemical Biology, researchers looking at Aspergillus flavus samples found they had molecules with interlocking rings, which had never been previously described. They dubbed them asperigimycins. Even with no modification, they found two of the four variants of asperigimycins they looked at had potent effects against leukemia cells. They then added a lipid that's also found in royal honey to another variant of asperigimycins and found the method killed just as many cancer cells as the drugs cytarabine and daunorubicin. Both drugs have been linked to a roughly 50 to 80 percent remission rate. The team also found the gene SLC46A3 helps molecules like asperigimycins exit lysosomes, tiny sacs that collect materials that enter cells. Qiuyue Nie, lead study author and a postdoctoral fellow at the University of Pennsylvania, said: 'This gene acts like a gateway. It doesn't just help asperigimycins get into cells, it may also enable other "cyclic peptides" to do the same.' Roughly 2,000 of these cyclic peptides have been shown to treat diseases like cancer and lupus, an autoimmune condition, but most need to be modified in some way. 'Knowing that lipids can affect how this gene transports chemicals into cells gives us another tool for drug development,' Nie said. However, the asperigimycins had no effect on breast, liver or lung cancer cells, siggesting they only disrupt cell division for certain types of cancer cells. Nie cautioned findings are still early but mark the beginning of an 'unexplored region with tremendous potential.' The team will next test asperigimycins in animals with the hope of moving on to human clinical trials. Dr Gao said: 'Nature has given us this incredible pharmacy. 'It's up to us to uncover its secrets. As engineers, we're excited to keep exploring, learning from nature and using that knowledge to design better solutions.'
